AURORA CANNABIS CHS CLASS ACTION CERTIFIED Français
TORONTO, June 9, 2025 /CNW/ - Thousands of Canadian cannabis users are hospitalized and diagnosed with Cannabinoid Hyperemesis Syndrome ("CHS") every year. CHS is a dangerous side effect that can develop from the regular use of cannabis products. CHS involves cyclical bouts of severe nausea, vomiting, and abdominal pain, which can persist for days and can occur as often as once every five minutes. In extreme cases, CHS can result in organ failure and even death.
On May 14, 2025, the Ontario Superior Court of Justice certified a national class action which alleges that Aurora Cannabis Inc, and Aurora Cannabis Enterprises Inc. negligently failed to warn consumers of the risk of developing CHS posed by the regular use of their cannabis products. This means that the action can now proceed as a class action. No findings of liability have been made against the defendants.
The action was commenced by V.T., a Canadian Forces veteran who was prescribed cannabis to treat medical conditions. V.T. purchased medicinal cannabis from the Defendants, and used it as prescribed, until they suffered two extreme bouts of nausea, vomiting and abdominal pain that were so severe V.T. had to be hospitalized. On the second E.R. visit, V.T. was diagnosed as suffering from CHS. The only certain cure for CHS is to stop consuming cannabis, which V.T. did, and is now symptom-free. None of the cannabis products that V.T. consumed contained any warning about CHS, nor is there any warning in the product monograph, or on Aurora's website.
The claim alleges that the Defendants knew, or should have known, of the risk of CHS arising from the regular use of their cannabis products, but negligently failed to provide any warning to consumers or prescribing physicians about the risk that they could develop CHS. The class action seeks to recover damages for the Class Members who developed CHS.
The class action is brought on behalf of all persons in Canada who purchased a Cannabis Product from Aurora Cannabis Inc. or Aurora Cannabis Enterprises Inc. (which includes MedReleaf) on or after February 1, 2014 to May 14, 2025 (the "Class Period") who were diagnosed or differentially diagnosed with CHS during the Class Period after consuming one or more Cannabis Products. Cannabis Products are the cannabis and/or synthetic cannabinoid resins, pills, lozenges, concentrates, oils, edibles, beverages, vapours, and raw and adulterated plant material cultivated, designed, manufactured, packaged, labeled, distributed, marketed, and/or sold by the Defendants.
The allegations contained in the Fresh as Amended Statement of Claim have not been proven in court, and the Defendants deny the Plaintiff's claims.
.
Sotos Class Actions
55 University Avenue, Suite 600
Toronto, ON M5J 2H7
[email protected]
1-877-294-9747 (toll free)
For media inquiries, please contact Margaret Waddell by phone at 416.977.2413 or by email at [email protected].
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vancouver Sun
6 hours ago
- Vancouver Sun
Letters to The Sun: Dilawri Foundation's donation is a life-changing gift
Re: Dilawri Foundation makes historic $60-million donation to VGH, UBC On behalf of the vast number of people who may be affected by heart disease and will need highly specialized care, but who at this time might not think of writing a letter to the editor, I want to say thank you to the Dilawri family for their enormous donation to the Vancouver General Hospital and UBC Hospital to create our own Mayo Clinic of the North. It is sure to benefit many of us for generations. With all the bad news in the world today, this is a beacon of goodness. Jane Murphy Thomas, Vancouver A daily roundup of Opinion pieces from the Sun and beyond. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Informed Opinion will soon be in your inbox. Please try again Interested in more newsletters? Browse here. Re: Postmedia's Kim Bolan one of three honoured for courageous reporting by Canadian Association of Journalists Congratulations to our incredible journalist Kim Bolan, who has risked her life many, many times when investigating horrid drug gangs, murders and other hard crime. She is incredibly brave at the journalism she pursues, and all for our sakes. She deserves this award and more for her persistent bravery. Caroline Duncan, North Vancouver It is quite evident that Canadian wildfire agencies and politicians are resigned to the public dealing with mass evacuations, unhealthy air, and destruction. Year after year, nothing changes. Shame. Compared to landslides, windstorms, floods and earthquakes, public emergencies from wildfires are the easiest to prevent. All fires start small, and when acted upon quickly with the right resources, mass evacuations can be avoided. As a former wildfire protection officer and incident management team member, I can assert that the right type and number of aircraft dispatched on discovery determines the outcome. With changing weather and changing landscape, fires need to be hit extra hard and fast from the air on initial attack, night and day. Ground crews are no match for moving crown fires. Wildfire agencies and politicians must give initial air attack a higher priority, otherwise we can expect more of the same — small fires turning into monsters. Clarence Friesen, Kelowna Re: Letter: Not all involuntary treatment is the same Thank you to The Sun for printing Marilyn Baker's letter. It is so important to keep clarifying the distinction between mental illness and addictions. These used to be considered very separate issues — and indeed they are. People suffering from both problems up until the early 1990s were called 'dual diagnosis' patients. The Vancouver General Hospital had a special ward that treated each condition quite separately — which worked fairly well. It is important to keep reminding people that these two things are not the same. As Baker's letter points out, there is clear, fact-based medical evidence that antipsychotic treatment for mental illness works. We do not yet know for certain about addictions, thus the argument continues. Meanwhile, patients with schizophrenia and other serious mental illnesses must be treated as early as possible, so they can live safely and with dignity in the community. Jane Duval, Vancouver Re: B.C. public-sector jobs have more than doubled under the NDP A great article in The Sun on June 7, but vital data is missing. The provincial government has tripled its debt in a vain effort to maintain existing services. They will take on more debt in the years ahead. There is little prospect of a significant increase in GDP, and GDP per capita and GDP per purchasing power parity are decreasing month by month and year by year. Any would-be job applicant from the target countries — the U.S. and Australia — who takes the trouble to look at our levels of taxation, the costs of living and the purchasing power parity here will not apply. They might also check out the number of people here in B.C. without a family doctor and waiting times to see a consultant or for surgery. The article mentioned population growth and the resulting increased pressure on all public services, but no figures. Canada's population grew by well over 1.5 million last year. That figure includes all legal immigrants, refugees and asylum seekers. On top of this comes temporary foreign workers, special permits and others. The article concentrated on salaries in the public sector, but added to these figures must be pensions, supplies and other essential running costs. So, a great article, but no solutions. Sadly, it will continue to be a case of crisis management and ever more public debt and higher taxes. Paul Rhodes, Sechelt
Cision Canada
9 hours ago
- Cision Canada
Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
HERZLIYA, Israel and CALGARY, AB, June 13, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries proudly announces the third party publication of a peer-reviewed narrative review in Cureus journal titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: The article discusses the therapeutic potential of long-acting synthetic cannabidiol (CBD) in addressing chronic pain—an urgent global health challenge for which safer, more effective treatments are desperately needed. Co-authored by leading pain specialists from institutions such as Johns Hopkins University and NYU School of Medicine, the review highlights that synthetic CBD administered through extended-release formulations could offer a well-tolerated, non-opioid analgesic alternative with the potential to significantly reduce reliance on addictive opioids. Chronic pain affects over 24% of adults in the United States alone, placing a significant burden on patients, healthcare systems, and economies*. Yet, long-term treatment options remain inadequate. NSAIDs pose cumulative toxicity risks, and opioids—while effective—present serious concerns including tolerance, dependency, and overdose risk. Globally, opioid misuse results in over 100,000 deaths annually (DOI: 10.1016/ The U.S. Food and Drug Administration (FDA) has emphasized the critical need for novel, non-addictive pain therapies through its "Guidance for Industry: Non-Opioid Analgesic Development Programs". Innocan's proprietary LPT-CBD platform is uniquely positioned to align with this regulatory focus. LPT-CBD is an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by various animal studies, LPT-CBD produces steady CBD plasma levels for up to four weeks, delivers prolonged pain relief, and is well tolerated, offering a promising alternative to current opioid medication and abuse. Innocan has initiated regulatory submissions in support of advancing LPT-CBD into human clinical trials. This progress marks a pivotal step toward realizing a first-in-class, non-opioid analgesic therapy tailored for the complexities of chronic pain management. "This publication underscores the urgent need for innovative, non-opioid analgesics that offer long-lasting efficacy," said Dr. Paul J. Christo, Associate Professor and Chief of the Division of Pain Medicine at the Johns Hopkins University School of Medicine and co-author of the article. "Liposomal synthetic CBD could offer a safe and scalable solution for a variety of painful conditions." "Given the current addiction crisis, there is an immediate need to replace opioids with safer, effective alternatives," noted Dr. Eugene Vortsman, Clinical Director of Addiction Medicine and Disease Management at Northwell Health and co-author of the article. "Long-acting synthetic CBD has real potential to shift the paradigm." Iris Bincovich, Chief Executive Officer of Innocan added:"We are thrilled by this breakthrough publication. Innocan is fully committed to advancing LPT-CBD toward clinical development, with the goal of delivering an innovative and safe non-opioid analgesic solution for chronic pain management." Reference Opioid crisis: addiction, overprescription, and insufficient primary prevention, The Lancet Regional Health – Americas 2023;23: 100557. DOI: 10.1016/ , Eugene Vortsman, Christopher Gharibo, Jo Ann K. LeQuang, Joseph V. Pergolizzi. Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review. Cureus Journal of Medical Science. DOI: 10.7759/cureus.81577 About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Global News
9 hours ago
- Global News
Cancer group warns Carney bill could weaken health standards. Why?
The Canadian Cancer Society is warning the Carney government that its legislation to eliminate interprovincial trade barriers could undermine health standards unless it's amended to add new safeguards. The legislation, which the government will try to push quickly through the House of Commons next week, looks to do two things — break down interprovincial barriers to trade and labour mobility and speed up approvals for major projects. The bill would allow provincial standards to displace federal ones to make it easier to sell Canadian-made goods within the country. 5:04 Breaking down provincial trade barriers with the 'One Canadian Economy' bill Rob Cunningham, senior policy analyst at the Canadian Cancer Society, says that could lead to unintended consequences because provincial rules are sometimes weaker, and warns of a possible resurgence of products banned by federal regulation, such as those containing asbestos. Story continues below advertisement He says the bill should be changed to exempt health and environment standards to avoid weakening them across the country. The Bloc Québécois, NDP and Green Party are accusing Prime Minister Mark Carney's government of trying to ram the bill through Parliament too quickly without sufficient study.
